| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Hospital & Healthcare Services
|
Compare with Industry peers |
| Website | http://www.transgenebiotek.com | |
| Market Cap | 55.24 Cr. | |
| Enterprise Value(EV) | 68.79 Cr. | 2023-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | -0.25 | Trailing Twelve Months Ending 2023-12 |
| Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2023-12 |
| Industry PE | 66.57 | Trailing Twelve Months Ending 2023-12 |
| Book Value / Share | 1.45 | Trailing Twelve Months Ending 2023-12 |
| Price to Book Value | 5.03 | Calculated using Price: 7.29 |
| Dividend Yield | 0.00 | Period Ending 2023-03 |
| No. of Shares Subscribed | 7.58 Cr. | 75,770,000 Shares |
| FaceValue | 10 | |
| About Transgene Biotek Ltd. | ||
| Transgene Biotek Ltd (TBL) was set up in 1991, and was probably the first true Biotechnology Company in India. It is listed on the Indian Stock Exchanges and is involved in the development of several cutting edge technologies. | ||
| 1 Day |
|
-4.95% |
| 1 Week |
|
-9.55% |
| 1 Month |
|
-17.72% |
| 3 Month |
|
-32.37% |
| 6 Month |
|
+80.89% |
| 1 Year |
|
+182.56% |
| 2 Year |
|
+83.17% |
| 5 Year |
|
+46.09% |
| 10 Year |
|
+58.13% |
| 9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
| Return on Equity (%) | -9.63 | -11.78 | -17.03 | -11.57 | -18.31 | -28.73 | -38 | -52.51 | -41.8 | |
| Return on Capital Employed (%) | -8.84 | -10.85 | -14.68 | -6.74 | -14.83 | -22.1 | -26.55 | -32.32 | -19.99 | |
| Return on Assets (%) | -5.45 | -6.56 | -7.77 | -3.35 | -4.84 | -6.39 | -6.45 | -6.84 | -4.15 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
| Shh. Funds | 191 | 174 | 59 | 52 | 44 | 33 | 22 | 17 | 11 | 11 | |
| Non Curr. Liab. | 127 | 127 | 127 | 120 | 120 | 120 | 120 | 121 | 121 | 121 | |
| Curr. Liab. | 25 | 11 | 12 | 14 | 13 | 14 | 14 | 9 | 10 | 11 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 344 | 313 | 198 | 187 | 177 | 167 | 157 | 147 | 142 | 142 | |
| Non Curr. Assets | 326 | 310 | 197 | 186 | 176 | 166 | 156 | 146 | 141 | 141 | |
| Curr. Assets | 18 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 344 | 313 | 198 | 187 | 177 | 167 | 157 | 147 | 142 | 142 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
| Net Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Other Income | 0 | 0 | 1 | 7 | 2 | 0 | 0 | 0 | 0 | 0 | |
| Total Income | 0 | 0 | 1 | 7 | 2 | 0 | 0 | 0 | 0 | 0 | |
| Total Expenditure | -2 | -1 | -3 | -2 | -1 | -1 | -1 | -1 | -1 | -1 | |
| PBIDT | -2 | -1 | -2 | 5 | 1 | -1 | 0 | 0 | 0 | 0 | |
| Interest | 0 | 0 | 0 | -1 | 0 | 0 | 0 | 0 | -1 | 0 | |
| Depreciation | -17 | -21 | -18 | -10 | -10 | -10 | -10 | -10 | -5 | -1 | |
| Taxation | -1 | ||||||||||
| Exceptional Items | |||||||||||
| PAT | -19 | -22 | -20 | -6 | -9 | -11 | -10 | -10 | -6 | -2 | |
| Minority Interest | |||||||||||
| Share Associate | |||||||||||
| Other Related Items | |||||||||||
| Consolidated Net Profit | -19 | -22 | -20 | -6 | -9 | -11 | -10 | -10 | -6 | -2 | |
| Adjusted EPS | -3 | -3 | -3 | -1 | -1 | -1 | -1 | -1 | -1 | 0 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Cash Fr. Operatn. | -2 | 4 | 6 | 0 | -1 | -2 | 0 | 0 | 0 | ||
| Cash Fr. Inv. | 1 | -5 | -6 | 3 | 2 | 0 | 0 | 0 | |||
| Cash Fr. Finan. | 1 | 1 | -2 | 0 | |||||||
| Net Change | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||
| Cash & Cash Eqvt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|
Mon, 01 Apr 2024
Closure of Trading Window Intimation of closure of Trading window as per the SEBI (Prohibition of Insider Trading) Regulation 2015. |
|
Wed, 21 Feb 2024
Announcement under Regulation 30 (LODR)-Newspaper Publication Newspaper Publication of 31st December 2023 Quarter Results. |
|
Wed, 14 Feb 2024
Board Meeting Outcome for Outcome Of Board Meeting 1) The Board has considered and approved the unaudited Consolidated & Stand-alone Financial Results of the company for the Quarter ended 31.12.2023 in accordance with the Indian Accounting Standards (IND-AS) as per Companies (Indian Accounting Standards) Rules 2015.2) Limited Review Report on the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended 31.12.2023 has also been approved. |
| Fri, 19 Apr 2024 |
Closing Below Previous Low
|
High Decrease in 1 Month
|
High Decrease in 3 Months
|
High Increase in 6 Months
|
High Increase in 1 Year
|
